FDA Policy for REMS Reqmts during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA is issuing this guidance to communicate its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements for the duration of the coronavirus pandemic public health emergency.
Read the Policy now
Related Education Resources.
All ResourcesGCSG App User Guide
Topic: Conference
Conference Training
Free
Direct-to-Patient Survey Results Summary
Topics: Health Care, Innovation, Supply Chain
Report
Free
Pelican webinar - Impact of COVID-19 on Cold Chain
Topics: Cold Chain, Supply Chain
Webinar
Free
